Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients

References

• Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019;95(1119):23–31. doi:10.1136/postgradmedj-2018-135729
   PubMed Web of Science ®Google Scholar
• Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35(1):157–165. doi:10.1016/S0272-6386(00)70316-7
   PubMed Web of Science ®Google Scholar
• Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China. Kidney Dis. 2018;4(1):10–19. doi:10.3390/molecules24010010
   Google Scholar
• Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739–3746. doi:10.1681/ASN.2016010093
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704. doi:10.1681/ASN.2009080861
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutierrez E, Rivera F, et al. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant. 2012;27(1):231–234. doi:10.1093/ndt/gfr285
   PubMed Web of Science ®Google Scholar
• Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care. Lancet. 2015;385(9981):1983–1992. doi:10.1016/S0140-6736(15)60731-0
   PubMed Web of Science ®Google Scholar
• Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1617–1630. doi:10.1681/ASN.2012010058
   PubMed Web of Science ®Google Scholar
• Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013;62(3):403–441. doi:10.1053/j.ajkd.2013.06.002
   PubMed Web of Science ®Google Scholar
• Rauch MC, San Martin A, Ojeda D, et al. Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects. Transpl Immunol. 2009;22(1–2):72–81. doi:10.1016/j.trim.2009.07.001
   PubMed Web of Science ®Google Scholar
• Cattran D, Brenchley P. Membranous nephropathy: thinking through the therapeutic options. Nephrol Dial Transplant. 2017;32(suppl_1):i22–i29. doi:10.1093/ndt/gfw404
   PubMed Web of Science ®Google Scholar
• Peng L, Wei SY, Li LT, He YX, Li B. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc. 2016;115(1):11–18. doi:10.1016/j.jfma.2015.07.021
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology. 2016;21(2):139–146. doi:10.1111/nep.12569
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Yadav AK, Kumar V, et al. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2(4):610–616. doi:10.1016/j.ekir.2017.02.004
   PubMed Web of Science ®Google Scholar
• Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44(3):385–401. doi:10.1016/S0272-6386(04)00809-1
   PubMed Web of Science ®Google Scholar
• Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2004;4:CD004293. doi:10.1002/14651858.CD004293.pub2
   PubMedGoogle Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–938. doi:10.1038/nm.1857
   PubMed Web of Science ®Google Scholar
• Stai S, Lioulios G, Christodoulou M, Papagianni A, Stangou M. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years? J Nephrol. 2022;36(2):551–561. doi:10.1007/s40620-022-01493-9
   PubMed Web of Science ®Google Scholar
• van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol. 2016;9(11):1463–1478. doi:10.1080/17512433.2016.1225497
   PubMed Web of Science ®Google Scholar
• Caro J, Gutierrez-Solis E, Rojas-Rivera J, et al. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant. 2015;30(3):467–474. doi:10.1093/ndt/gfu306
   PubMed Web of Science ®Google Scholar
• Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010;339(3):233–238. doi:10.1097/MAJ.0b013e3181ca3a7d
   PubMed Web of Science ®Google Scholar
• Seitz-Polski B, Debiec H, Rousseau A, et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J Am Soc Nephrol. 2018;29(2):401–408. doi:10.1681/ASN.2017070734
   PubMed Web of Science ®Google Scholar
• Wei SY, Wang YX, Li JS, et al. Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy. Am J Nephrol. 2016;43(2):129–140. doi:10.1159/000445361
   PubMed Web of Science ®Google Scholar
• Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One. 2017;12(3):e0173201. doi:10.1371/journal.pone.0173201
   PubMed Web of Science ®Google Scholar
• Berthoux F, Mariat C, Maillard N. Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant. 2013;28(Suppl 4):iv160–iv166. doi:10.1093/ndt/gft286
   PubMed Web of Science ®Google Scholar
• Nowak KL, You Z, Gitomer B, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29(2):571–578. doi:10.1681/ASN.2017070819
   PubMed Web of Science ®Google Scholar
• Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008;294(4):F685–F696. doi:10.1152/ajprenal.00324.2007
   PubMed Web of Science ®Google Scholar
• de Vries AP, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417–426. doi:10.1016/S2213-8587(14)70065-8
   PubMed Web of Science ®Google Scholar
• Huh H, Lee H, Lee JP, et al. Factors affecting the long-term outcomes of idiopathic membranous nephropathy. BMC Nephrol. 2017;18(1):104. doi:10.1186/s12882-017-0525-6
   PubMedGoogle Scholar
• Xu J, Zhang W, Xu Y, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013;181:152–162.
   PubMed Web of Science ®Google Scholar
• Liang Q, Li H, Xie X, Qu F, Li X, Chen J. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail. 2017;39(1):512–518. doi:10.1080/0886022X.2017.1325371
   PubMed Web of Science ®Google Scholar
• Di J, Qian Q, Yang M, et al. Efficacy and safety of long-course tacrolimus treatment for idiopathic membranous nephropathy. Exp Ther Med. 2018;16(2):979–984. doi:10.3892/etm.2018.6211
   PubMed Web of Science ®Google Scholar
• Ume AC, Wenegieme TY, Williams CR. Calcineurin inhibitors: a double-edged sword. Am J Physiol Renal Physiol. 2021;320(3):F336–F341. doi:10.1152/ajprenal.00262.2020
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. doi:10.2215/CJN.04800908
   PubMed Web of Science ®Google Scholar
• Lin W, Li HY, Lin S, Zhou T. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis. Drug Des Devel Ther. 2019;13:2179–2186. doi:10.2147/DDDT.S209211
   PubMed Web of Science ®Google Scholar